Sarepta is making a bold bet on genetic medicine
January 10, 2018 at 12:04 PM EST
Sarepta Therapeutics Inc. is best known for the storm of controversy around its Duchenne muscular dystrophy therapy Exondys 51, which was approved in 2016, but CEO Douglas Ingram is betting that soon, the company will be better known for something else entirely.
